ConCallIQ
Go Pro
Home › Biocon › Guidance

Biocon Management Guidance Tracker

8 forward-looking guidance items tracked across 2 quarters.

Margins

Q3 FY26Annualized interest savings of ~₹300 crore from FY27Tracked

Management expects annualized interest cost savings of approximately ₹300 crore starting FY27, following the retirement of structured debt.

Q3 FY26Biosimilar EBITDA margin to be in mid-20s for full year FY26Tracked

Management reiterated that biosimilar EBITDA margin for the full year FY26 will be in the mid-20s, despite Q3 margin of 28%.

Q4 FY26EBITDA margin expansion of ~200bps in FY26 on like-to-like basisTracked

Margins improved to 22% for FY26; management expects further operating leverage as new products ramp up.

Capex

Q3 FY26Capex to moderate to <$225 million and further declineTracked

Group capex has moderated from ~$275 million to less than $225 million, and will decline further as Malaysia insulin capacity buildup completes.

Expansion

Q3 FY26Insulin drug product capacity to double in FY27Tracked

The Malaysia insulin drug product capacity expansion is expected to go commercial in FY27, doubling current capacity.

Revenue

Q4 FY26Biosimilar revenue growth of 16% in FY26 on like-to-like basisTracked

Management expects continued growth in biosimilars, with new product launches scaling in H2 FY27.

Other

Q4 FY26Net debt reduction to ~$1.1B from $1.5B in March 2025Active

Free cash flow will be prioritized for deleveraging; interest cost savings of ~₹75 Cr per quarter expected.

Growth

Q4 FY26Aflibercept (Yesafili) launch in US in H2 FY27Tracked

Settlement with originator allows entry; management expects meaningful revenue contribution from H2.